Abstract
Malignant gliomas are the most common primary central nervous system tumors, and the most aggressive and frequent form is the World Health Organization (WHO) grade IV astrocytoma, or glioblastoma. The standard treatment of glioblastoma consists of aggressive resection, radiation therapy, and concomitant and adjuvant treatment with the DNAalkylating agent temozolomide. Despite treatment, the prognosis is dismal for the vast majority of glioblastoma patients, with over 90% of patients succumbing to the disease within 5 years and a median survival of just over 1 year after diagnosis. There is clearly a great need for the development of therapeutic agents targeting pathways driving glioma malignancy, including cell proliferation, invasion, survival, as well as angiogenesis and pathways leading to resistance to cytotoxic therapies. Identification and validation of biomarkers predictive of response to therapy for patient stratification is an essential component of the development of targeted therapies. Comprehensive molecular characterization of tumor tissues is becoming prevalent, and developing approaches to integrate and bring this knowledge to the clinic will fuel the incorporation of targeted therapy in the management of malignant gliomas.
Keywords: Glioblastoma, glioma, targeted therapy, biomarkers, cell signaling, molecular profiling, clinical trials, chemotherapy
Current Signal Transduction Therapy
Title:Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Volume: 8 Issue: 1
Author(s): Ana C. deCarvalho, Norman L. Lehman and Tom Mikkelsen
Affiliation:
Keywords: Glioblastoma, glioma, targeted therapy, biomarkers, cell signaling, molecular profiling, clinical trials, chemotherapy
Abstract: Malignant gliomas are the most common primary central nervous system tumors, and the most aggressive and frequent form is the World Health Organization (WHO) grade IV astrocytoma, or glioblastoma. The standard treatment of glioblastoma consists of aggressive resection, radiation therapy, and concomitant and adjuvant treatment with the DNAalkylating agent temozolomide. Despite treatment, the prognosis is dismal for the vast majority of glioblastoma patients, with over 90% of patients succumbing to the disease within 5 years and a median survival of just over 1 year after diagnosis. There is clearly a great need for the development of therapeutic agents targeting pathways driving glioma malignancy, including cell proliferation, invasion, survival, as well as angiogenesis and pathways leading to resistance to cytotoxic therapies. Identification and validation of biomarkers predictive of response to therapy for patient stratification is an essential component of the development of targeted therapies. Comprehensive molecular characterization of tumor tissues is becoming prevalent, and developing approaches to integrate and bring this knowledge to the clinic will fuel the incorporation of targeted therapy in the management of malignant gliomas.
Export Options
About this article
Cite this article as:
C. deCarvalho Ana, L. Lehman Norman and Mikkelsen Tom, Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010003
DOI https://dx.doi.org/10.2174/1574362411308010003 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Multivariate Statistical Tools for the Evaluation of Proteomic 2D-maps:Recent Achievements and Applications
Current Proteomics Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia via mir-491
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Synthesis of Biologically Relevant Selenium-containing 5-Membered Heterocycles
Current Organic Chemistry Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapy Based on the Regulation of Thiol-dependent Redox Systems
Current Medicinal Chemistry